Reviewing SiBone (NASDAQ:SIBN) and Artivion (NYSE:AORT)

SiBone (NASDAQ:SIBN) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

98.1% of SiBone shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SiBone and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Artivion	2.55%	7.15%	3.63%

Valuation & Earnings

This table compares SiBone and Artivion”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93 million	3.27	-$18.90 million	($0.39)	-37.97
Artivion	$441.33 million	2.50	$9.77 million	$0.24	94.77

Artivion has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for SiBone and Artivion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	6	0	2.71
Artivion	0	1	7	0	2.88

SiBone presently has a consensus price target of $23.00, indicating a potential upside of 55.30%. Artivion has a consensus price target of $47.83, indicating a potential upside of 110.31%. Given Artivion’s stronger consensus rating and higher possible upside, analysts plainly believe Artivion is more favorable than SiBone.

Volatility and Risk

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Summary

Artivion beats SiBone on 12 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.